Replimune Group, Inc.

REPL

US76029N1063

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:44:12 29/06/2024 am IST			5-day change	1st Jan Change
8.89 ^USD	+4.34%		+5.18%	+6.05%

24/06	Replimune Group, Inc.(NasdaqGS:REPL) dropped from S&P Biotechnology Select Industry Index	CI
13/06	Replimune Group Signs $100 Million PIPE Deal with Institutional Investors	MT

Replimune Group, Inc.(NasdaqGS:REPL) dropped from S&P Biotechnology Select Industry Index

June 24, 2024

Latest news about Replimune Group, Inc.

Replimune Group, Inc.(NasdaqGS:REPL) dropped from S&P Biotechnology Select Industry Index	24/06	CI
Replimune Group Signs $100 Million PIPE Deal with Institutional Investors	13/06	MT
Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding	12/06	CI
HC Wainwright Adjusts Price Target on Replimune to $17 From $12, Maintains Buy Rating	07/06	MT
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	07/06	MT
Sector Update: Health Care	07/06	MT
Replimune Shares Rise as Study Data on Melanoma Treatment Improves	06/06	MT
Transcript : Replimune Group, Inc. - Special Call	06/06
Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma	06/06	CI
Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology Annual Meeting	03/06	CI
Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	16/05	CI
Replimune Group Provides Interim Results for Skin Cancer Therapy	08/04	MT
Replimune Group, Inc. Announces Management Changes	26/03	CI
Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024	26/03	CI
Transcript : Replimune Group, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 10:45 AM	14/03
Wedbush Raises Replimune Group's PT to $16 From $14 After Adjusting Financing Assumptions, Keeps Outperform Rating	09/02	MT
Replimune Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02	CI
Transcript : Replimune Group, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 11:15 AM	09/01
Wedbush Cuts Replimune Group's PT to $14 From $52 After Narrow Complete Response Rate Miss in Phase 2 Trial of Skin Cancer Treatment Candidate; Keeps Outperform Rating	06/12	MT
Barclays Lowers Price Target on Replimune Group to $13 From $50, Keeps Overweight Rating	06/12	MT
Sector Update: Health Care Stocks Ease Late Afternoon	06/12	MT
Sector Update: Health Care	06/12	MT
Replimune Group Shares Slide as Trial of Skin Cancer Treatment Candidate Failed to Meet Primary Endpoints	06/12	MT
Transcript : Replimune Group, Inc. - Special Call	05/12
Replimune's skin cancer drug fails in late-stage study	05/12	RE

Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Companyâs proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.52 USD

Average target price

14.33 USD

Spread / Average Target

+68.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
REPLIMUNE GROUP, INC.	+6.05%	52Cr
LONZA GROUP AG	+38.65%	3.91TCr
IQVIA HOLDINGS INC.	-8.87%	3.88TCr
ALNYLAM PHARMACEUTICALS, INC.	+27.43%	3.12TCr
ICON PUBLIC LIMITED COMPANY	+11.21%	2.59TCr
CELLTRION, INC.	-13.50%	2.58TCr
UNITED THERAPEUTICS CORPORATION	+43.91%	1.41TCr
MEDPACE HOLDINGS, INC.	+34.65%	1.31TCr
BIO-TECHNE CORPORATION	-7.93%	1.13TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.84%	1.07TCr

Other Biotechnology & Medical Research